Antihypertensive effects of aspirin: What is the evidence?

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 282-289

  Bautista, Leonelo E ^a   Vera, Lina M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

Antihypertensive treatment; Aspirin; Blood pressure; Drug chronotherapy; Hypertension; Meta analysis; Nonsteroidal anti inflammatory agents

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ISRADIPINE; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PLACEBO;

ANTIHYPERTENSIVE ACTIVITY; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; HYPERTENSION; INCIDENCE; LOW DRUG DOSE; REVIEW; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; RISK; RISK FACTORS;

EID: 77956267897     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0115-5     Document Type: Review

References (50)

1. JR Vane 1971 Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 232 235 1:CAS:528: DyaE3MXltVyjur4%3D 5284360
2. RN Dubois SB Abramson L Crofford, et al. 1998 Cyclooxygenase in biology and disease FASEB J 12 1063 1073 1:CAS:528:DyaK1cXlvFWntbY%3D 9737710
3. RC Harris MD Breyer 2001 Physiological regulation of cyclooxygenase-2 in the kidney Am J Physiol Renal Physiol 281 F1 F11 1:CAS:528:DC%2BD3MXltVyntbk%3D 11399641
4. UA Ajani ES Ford KJ Greenland, et al. 2006 Aspirin use among U.S. adults: behavioral risk factor surveillance system Am J Prev Med 30 74 77 10.1016/j.amepre.2005.08.042 16414427
5. M Pignone GK Anderson K Binns, et al. 2007 Aspirin use among adults aged 40 and older in the United States: results of a national survey Am J Prev Med 32 403 407 10.1016/j.amepre.2007.01.010 17478266
6. JS Berger MC Roncaglioni F Avanzini, et al. 2006 Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials JAMA 295 306 313 10.1001/jama.295.3.306 1:CAS:528:DC%2BD28XlsVSjsA%3D%3D 16418466
7. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 71 86 10.1136/bmj.324. 7329.71
8. AG Johnson TV Nguyen RO Day 1994 Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis Ann Intern Med 121 289 300 1:STN:280:DyaK2czhtFGnsg%3D%3D 8037411
9. JE Pope JJ Anderson DT Felson 1993 A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure Arch Intern Med 153 477 484 10.1001/archinte.153.4.477 1:STN:280:DyaK3s7msl2kug%3D%3D 8435027
10. S MacMahon R Peto J Cutler, et al. 1990 Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 335 765 774 10.1016/0140-6736(90)90878-9 1:STN:280:DyaK3c3gsFegug%3D%3D 1969518
11. R Dersimonian R Kacker 2007 Random-effects model for meta-analysis of clinical trials: an update Contemp Clin Trials 28 105 114 10.1016/j.cct.2006.04. 004 16807131
12. RC Hermida JR Fernandez DE Ayala, et al. 1994 Time-dependent effects of ASA administration on blood pressure in healthy subjects Chronobiologia 21 201 213 1:CAS:528:DyaK2MXjvVOgsb4%3D 7729237
13. RC Hermida JR Fernandez DE Ayala, et al. 1997 Influence of aspirin usage on blood pressure: dose and administration-time dependencies Chronobiol Int 14 619 637 10.3109/07420529709001452 1:CAS:528:DyaK2sXnsV2jurg%3D 9360028
14. RC Hermida DE Ayala C Calvo JE Lopez 2005 Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients J Am Coll Cardiol 46 975 983 10.1016/j.jacc.2004.08.071 1:CAS:528:DC%2BD2MXhtVWhu7vI 16168278
15. RC Hermida DE Ayala C Calvo, et al. 2005 Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives Hypertension 46 1060 1068 10.1161/01.HYP.0000172623.36098.4e 1:CAS:528:DC%2BD2MXhtVektr%2FM 16087788
16. RC Hermida DE Ayala A Mojon JR Fernandez 2009 Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension Am J Hypertens 22 896 903 10.1038/ajh.2009.83 1:CAS:528:DC%2BD1MXptlGru78%3D 19407805
17. RC Hermida DE Ayala C Calvo, et al. 2004 Response: Aspirin administered at bedtime as opposed to upon wakening has an effect on ambulatory blood pressure: further evidence Hypertension 43 e22 e23 10.1161/01.HYP.0000120849. 80528.35 1:CAS:528:DC%2BD2cXjtVeksrw%3D
18. G Parati JA Staessen 2003 Hypertension drug trials based on ambulatory blood pressure monitoring: When is a double-blind controlled design needed? J Hypertens 21 1237 1239 10.1097/00004872-200307000-00005 1:CAS:528: DC%2BD3sXmsVait7Y%3D 12817164
19. BA Gould S Mann AB Davies, et al. 1981 Does placebo lower blood-pressure? Lancet 2 8260-8261 1377 1381 10.1016/S0140-6736(81)92799-9 1:STN:280: DyaL38%2FnvFOlsg%3D%3D 6118757
20. G Mancia S Omboni G Parati, et al. 1995 Lack of placebo effect on ambulatory blood pressure Am J Hypertens 8 311 315 10.1016/0895-7061(94)00250-F 1:STN:280:DyaK2MzhsVygsQ%3D%3D 7794581
21. JA Staessen L Thijs L Bieniaszewski, et al. 1996 Ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action Hypertension 27 414 420 1:STN:280:DyaK287pslWitw%3D%3D 8698447
22. P Howe P Phillips R Saini K Kassler-Taub 1999 The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group Clin Exp Hypertens 21 1373 1396 10.3109/10641969909070855 1:CAS:528: DyaK1MXnvFSjuro%3D 10574419
23. L Hansson T Hedner B Dahlof 1992 Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point Blood Press 1 113 119 10.3109/ 08037059209077502 1:STN:280:DyaK2M3mtFGgsQ%3D%3D 1366259
24. DH Smith JM Neutel Y Lacourciere J Kempthorne-Rawson 2003 Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements J Hypertens 21 1291 1298 10.1097/00004872-200307000-00016 1:CAS:528:DC%2BD3sXmsVaitLc%3D 12817175
25. L Hansson A Zanchetti SG Carruthers, et al. 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1755 1762 10.1016/S0140-6736(98)04311-6 1:CAS:528:DyaK1cXksV2qtrY%3D 9635947
26. GA Mansoor WB White 1994 Contribution of ambulatory blood pressure monitoring to the design and analysis of antihypertensive therapy trials J Cardiovasc Risk 1 136 142 1:STN:280:DyaK2MzjtVKgsg%3D%3D 7606625
27. RA Parker 2009 Studies should be controlled, randomized, and blinded Clin Pharmacol Ther 85 461 463 10.1038/clpt.2009.13 1:CAS:528:DC%2BD1MXkslKqurs%3D 19381148
28. EA Chrischilles RB Wallace 1993 Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population J Gerontol 48 M91 M96 1:STN:280:DyaK3s3ks1Grsg%3D%3D 8482817
29. A Whelton 1999 Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications Am J Med 106 13S 24S 10.1016/S0002-9343(99)00113-8 1:CAS:528:DyaK1MXjvFOns74%3D 10390124
30. JV Gainer JD Morrow A Loveland, et al. 1998 Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects N Engl J Med 339 1285 1292 10.1056/NEJM199810293391804 1:CAS:528:DyaK1cXnt12kt7Y%3D 9791144
31. A Magagna B Abdel-Haq S Favilla, et al. 1994 Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients Blood Press 3 236 241 10.3109/08037059409102263 1:STN:280: DyaK2M%2Fos1Ojtw%3D%3D 7994448
32. F Avanzini G Palumbo C Alli, et al. 2000 Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)-Hypertension study Am J Hypertens 13 611 616 10.1016/S0895-7061(00)00231-4 1:CAS:528: DC%2BD3cXltlOgu7o%3D 10912743
33. JJ Nawarskas RR Townsend MD Cirigliano SA Spinler 1999 Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan Am J Hypertens 12 784 789 10.1016/S0895-7061(99)00037-0 1:STN:280: DyaK1MvgvVenug%3D%3D 10480471
34. SR Smith TM Coffman LP Svetkey 1993 Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril J Am Soc Nephrol 4 1133 1139 1:STN:280:DyaK2c7jsl2ntg%3D%3D 8305640
35. J Polónia I Boaventura G Gama, et al. 1995 Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients J Hypertens 13 925 931 10.1097/00004872-199508000-00014 8557971
36. MD Guazzi J Campodonico F Celeste, et al. 1998 Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction Clin Pharmacol Ther 63 79 86 10.1016/S0009-9236(98)90123-0 1:CAS:528: DyaK1cXhtVGhu7g%3D 9465844
37. TJ Moore FR Crantz NK Hollenberg, et al. 1981 Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension Hypertension 3 168 173 1:STN:280:DyaL3M7ms1KqsA%3D%3D 6260645
38. P Tison L Ulicna Z Jakubovska, et al. 1994 Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension Am J Hypertens 7 46S 49S 1:STN:280:DyaK2M%2FjtlSjsw%3D%3D 7946179
39. EZ Fisman E Grossman M Motro A Tenenbaum 2002 Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors J Hum Hypertens 16 379 383 10.1038/sj.jhh.1001406 1:CAS:528:DC%2BD38XltVKitLg%3D 12037691
40. RH Boger SM Bode-Boger P Kramme, et al. 1996 Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid Br J Clin Pharmacol 42 721 727 10.1046/j.1365-2125.1996.00480.x 1:STN:280:DyaK2s7is1GisA%3D%3D 8971427
41. A Zanchetti L Hansson G Leonetti, et al. 2002 Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy J Hypertens 20 1015 1022 10.1097/00004872-200205000-00038 1:CAS:528: DC%2BD38XksVGmtLo%3D 12011664
42. UC Dubach B Rosner T Sturmer 1991 An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987) N Engl J Med 324 155 160 1:STN:280:DyaK3M%2FnsVansw%3D%3D 1984193
43. J Dedier MJ Stampfer SE Hankinson, et al. 2002 Nonnarcotic analgesic use and the risk of hypertension in US women Hypertension 40 604 608 10.1161/01.HYP.0000035856.77718.DA 1:CAS:528:DC%2BD38XpsFSgu7c%3D 12411450
44. JP Forman MJ Stampfer GC Curhan 2005 Non-narcotic analgesic dose and risk of incident hypertension in US women Hypertension 46 500 507 10.1161/01.HYP.0000177437.07240.70 1:CAS:528:DC%2BD2MXptVWkurc%3D 16103274
45. GC Curhan WC Willett B Rosner MJ Stampfer 2002 Frequency of analgesic use and risk of hypertension in younger women Arch Intern Med 162 2204 2208 10.1001/archinte.162.19.2204 1:CAS:528:DC%2BD38XovVWjurw%3D 12390063
46. T Kurth CH Hennekens T Sturmer, et al. 2005 Analgesic use and risk of subsequent hypertension in apparently healthy men Arch Intern Med 165 1903 1909 10.1001/archinte.165.16.1903 16157836
47. JP Forman EB Rimm GC Curhan 2007 Frequency of analgesic use and risk of hypertension among men Arch Intern Med 167 394 399 10.1001/archinte.167.4.394 17325302
48. J Wang CD Mullins M Mamdani, et al. 2007 New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study Ann Pharmacother 41 937 943 10.1345/aph.1H659 1:CAS:528:DC%2BD2sXnsFKmsbw%3D 17488830
49. LE Bautista P Lopez-Jaramillo LM Vera, et al. 2001 Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 19 857 861 10.1097/00004872-200105000-00004 1:CAS:528:DC%2BD3MXktVWms7Y%3D 11393667
50. HD Sesso JE Buring N Rifai, et al. 2003 C-reactive protein and the risk of developing hypertension JAMA 290 2945 2951 10.1001/jama.290.22.2945 1:CAS:528:DC%2BD3sXpvVKhtb8%3D 14665655